Perhaps most reassuring about semaglutide’s cardiovascular benefits is their durability over time. The protection against major adverse cardiac events persisted throughout the study’s follow ...

Ozempic and Wegovy, which are based on the active ingredient semaglutide, may provide notable advantages for cardiac health, including a decreased risk of stroke or heart attack, irrespective of ...

At just three months, before dose titration was over, participants on semaglutide had a noted decreased risk for stroke, heart attack, or cardiovascular death, with additional benefits at six months.

The anti-obesity medication semaglutide may help to prevent heart attacks and other major adverse cardiac events among overweight people who have cardiovascular disease, whether or not they also ...

In SELECT, semaglutide showed a 20% reduction in major adverse cardiovascular events (MACE) – including cardiovascular death, non-fatal heart attack, or non-fatal stroke – with the benefits ...

The anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with overweight or obesity who ...

Semaglutide boosts heart health, weight loss but may lead to gut problems. ... Untangling different health benefits resulting from semaglutide from those resulting from weight loss can be difficult.

A new meta-analysis confirms that semaglutide drugs like Ozempic are not only effective for weight loss, but can also protect the heart. However, certain doses and delivery systems can lead to ...

Among patients who have obesity-related heart failure with preserved ejection fraction (HFpEF), once-weekly semaglutide 2.4 mg (Wegovy; Novo Nordisk) induces greater weight loss in women than in men ...

Semaglutide’s cardiovascular benefits remain effective in individuals with impaired kidney function, offering heart protection even with reduced renal health.

Citation: Semaglutide's cardiovascular benefits are maintained in people with impaired kidney function, research finds (2024, September 11) retrieved 16 May 2025 from https://medicalxpress.com ...

Treatment was discontinued more often in the semaglutide group, primarily driven by gastrointestinal disorders (14.7% vs 9.0% in the heart failure groups; and 17.2% vs 7.9% in non-heart failure ...